The Effect of Hydrogen Rich Water Intake on Acute Body Response and Following Recovery After 5 km Run in Untrained Men
The Effect of Hydrogen Rich Water Intake on Acute Body Response and Following Recovery After Single 5 km Run in Endurance-untrained Men. Randomized, Double Blinded, Placebo Controlled, Cross-over Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jakub Krejci, PhD
- Phone Number: +420585636404
- Email: jakub.krejci@upol.cz
Study Contact Backup
- Name: Michal Valenta, Mgr
- Phone Number: +420777638981
- Email: michal.valenta@upol.cz
Study Locations
-
-
-
Olomouc, Czechia, 77111
- Palacky University, Faculty of Physical Culture
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- No experience with endurance training.
- Good health condition.
- Signed informed content.
Exclusion Criteria:
- Acute health problems.
- Not following instructions (free of any supplements three weeks before experiment, free of any medicaments, no caffeine at least 24 hours before experiment).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hydrogen rich water
Hydrogen rich water supplied in 420 ml packages.
Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
|
Hydrogen-rich water with molecular hydrogen concentration 0.9 ppm.
Other Names:
|
|
Placebo Comparator: Placebo
Tap water supplied in 420 ml packages.
Two days before testing - 2 packages (morning and evening), one day before testing - 3 packages (morning, afternoon, and evening), testing day - 4 packages (2 h before the run, 1 h before the run, immediately after the run, and 1 h after the run), 9 packages in total.
|
Tap water with molecular hydrogen concentration 0.0 ppm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Run time
Time Frame: Change between values before and after 7 days of crossover.
|
The 5 km run is performed on a 200 m long indoor track.
The running time (total time and laps times) of each runner is measured by one qualified timekeeper, which does not change between trials.
The time is measured to the nearest 0.1 s with manual stopwatch.
|
Change between values before and after 7 days of crossover.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate during running
Time Frame: Change between values before and after 7 days of crossover.
|
Heart rate during the 5 km run is continuously recorded using a heart rate monitor (Polar Team Coach, Polar, Kempele, Finland).
|
Change between values before and after 7 days of crossover.
|
|
Rating of perceived exertion
Time Frame: Change between values before and after 7 days of crossover.
|
The subject is asked to score subjective rating of perceived exertion using the scale developed by Borg.
All subjects are familiar with the Borg scale before testing.
We use the scale ranging from 6 (no exertion at all) to 20 (maximal exertion).
The rating of perceived exertion is scored immediately after the run.
|
Change between values before and after 7 days of crossover.
|
|
Blood lactate
Time Frame: Change between values before and after 7 days of crossover.
|
Blood lactate concentration is evaluated based on blood samples taken from the fingertip.
An alcohol wipe is used to clean the fingertip and the skin is punctured with a lancet.
The first drop is wiped away and the second drop is used.
Lactate Scout+ analyzer (EKF Diagnostics, Cardiff, United Kingdom) is used for lactate sampling.
Blood lactate is evaluated after the run.
|
Change between values before and after 7 days of crossover.
|
|
Reactive strength index
Time Frame: Change between values before and after 7 days of crossover.
|
Reactive strength index is determined in a 5 maximum hop test performed on a mobile force platform (FP8, HUR Labs, Tampere, Finland).
Each subject is instructed to maximize the jump height and minimize the ground contact time.
The first hop served as a countermovement jump and is excluded from the analysis.
The remaining 4 hops are averaged and reported as the outcome.
The reactive strength index is determined before and after the run, 1 h and 4 h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Subjective perceived muscle soreness
Time Frame: Change between values before and after 7 days of crossover.
|
Visual analogue scale (VAS) is used to assess lower limb muscle soreness.
The VAS scale is a 100 mm long line marked with the numbers 0 (no pain) and 100 (worst imaginable pain).
The VAS is assessed immediately, 1 h, 4h, and 24 h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Protein carbonyls
Time Frame: Change between values before and after 7 days of crossover.
|
Protein carbonyls are detected from vein blood sample which is taken from the inside of the elbow by a healthcare specialist.
The blood is taken into heparinized vacuum tubes.
These is then centrifugated at 1000 g.
Subsequently, the blood plasma is separated into cryotubes and frozen at -80 °C until biochemical analysis.
Protein carbonyls concentration is determined by ELISA method in accordance with the manufacturer´s manual (Protein Carbonyl Content Assay Kit MAK094, Sigma-Aldrich, Saint Louis, USA).
Protein carbonyls are sampled before and after the run, 1 h and 4 h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Malondialdehydes
Time Frame: Change between values before and after 7 days of crossover.
|
Malondialdehydes are detected from vein blood sample which is taken from the inside of the elbow by a healthcare specialist.
The blood is taken into heparinized vacuum tubes.
These is then centrifugated at 1000 g.
Subsequently, the blood plasma is separated into cryotubes and frozen at -80 °C until biochemical analysis.
The concentration of malondialdehydes in plasma samples as lipid peroxidation products is determined using the Lipid Peroxidation Assay Kit MAK085 (Sigma-Aldrich, Saint Louis, USA) according to the manufacturer's instructions.
Malondialdehydes are sampled before and after the run, 1 h and 4 h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Heart rate variability - heart rate
Time Frame: Change between values before and after 7 days of crossover.
|
Heart rate (HR) is measured using the DiANS PF8 ECG device (DIMEA Group, Olomouc, Czech Republic).
ECG sampling is performed during an orthoclinostatic maneuver in a calm room without acoustic and visual disturbances.
HR is measured before and after the run, 1h and 4h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Heart rate variability - RMSSD
Time Frame: Change between values before and after 7 days of crossover.
|
Root mean square successive difference of RR intervals (RMSSD) is measured using the DiANS PF8 ECG device (DIMEA Group, Olomouc, Czech Republic).
ECG sampling is performed during an orthoclinostatic maneuver in a calm room without acoustic and visual disturbances.
RMSSD is measured before and after the run, 1h and 4h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Heart rate variability - SDNN
Time Frame: Change between values before and after 7 days of crossover.
|
Standard deviation of RR intervals (SDNN) is measured using the DiANS PF8 ECG device (DIMEA Group, Olomouc, Czech Republic).
ECG sampling is performed during an orthoclinostatic maneuver in a calm room without acoustic and visual disturbances.
SDNN is measured before and after the run, 1h and 4h after the run.
|
Change between values before and after 7 days of crossover.
|
|
Heart rate variability - LF/HF
Time Frame: Change between values before and after 7 days of crossover.
|
Ratio of low-frequency to high-frequency power (LF/HF) is measured using the DiANS PF8 ECG device (DIMEA Group, Olomouc, Czech Republic).
ECG sampling is performed during an orthoclinostatic maneuver in a calm room without acoustic and visual disturbances.
LF/HF is measured before and after the run, 1h and 4h after the run.
|
Change between values before and after 7 days of crossover.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michal Valenta, Mgr, Palacky University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FTK_2023_14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.